BNP Paribas Financial Markets
PRVB

BNP Paribas Financial Markets’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

BNP Paribas Financial Markets’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27,269
Closed -$657K – 4071
2023
Q1 		$657K Buy
27,269
+16,309
+149% +$205K ﹤0.01% 2574
2022
Q4 		$116K Sell
10,960
-10,557
-49% -$85.2K ﹤0.01% 3204
2022
Q3 		$96.8K Buy
21,517
+4,840
+29% +$22.1K ﹤0.01% 3787
2022
Q2 		$66.7K Buy
16,677
+11,165
+203% +$52.9K ﹤0.01% 3483
2022
Q1 		$40.3K Sell
5,512
-13,771
-71% -$82.4K ﹤0.01% 3600
2021
Q4 		$108K Buy
19,283
+6,191
+47% +$39.3K ﹤0.01% 3570
2021
Q3 		$83.8K Buy
13,092
+6,278
+92% +$40.3K ﹤0.01% 3340
2021
Q2 		$57.4K Sell
6,814
-35
-0.5% -$282 ﹤0.01% 3216
2021
Q1 		$71.9K Sell
6,849
-2,312
-25% -$32.5K ﹤0.01% 3495
2020
Q4 		$155K Sell
9,161
-1,994
-18% -$29.9K ﹤0.01% 2998
2020
Q3 		$143K Buy
11,155
+9,544
+592% +$121K ﹤0.01% 2918
2020
Q2 		$22.7K Buy
+1,611
New +$20.3K ﹤0.01% 3345

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BNP Paribas Financial Markets's PRVB Position: Q2 2023 in Review

BNP Paribas Financial Markets sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 27,269 shares — an estimated $657K sold.

BNP Paribas Financial Markets first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $657K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • BNP Paribas Financial Markets reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 27,269 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $657K.
  • BNP Paribas Financial Markets first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • BNP Paribas Financial Markets's Provention Bio, Inc. Common Stock position peaked at $657K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2023, filed 9 Aug 2023.